GlassScriptPhysician profile
Amy K Davis
NPI 1386820744
$744.84
in general payments reported to CMS, 2019-2025
22 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $115 · 2023: $117 · 2024: $49.30 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.02 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.76 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $64.63 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $59.56 | 2021-2025 | |
| Amgen INC. | $59.04 | 2021-2025 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $54.85 | 2023-2025 | |
| Astellas Pharma US INC | $53.63 | 2025 | Vyloy |
| Inspire Medical Systems, INC. | $43.58 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $29.58 | 2023 | Xarelto |
| Exact Sciences Corporation | $25.23 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $25.13 | 2025 | Rexulti |
| Abbott Laboratories | $24.95 | 2025 | Cardiomems |
| Phathom Pharmaceuticals, INC. | $20.08 | 2025 | Voquezna |
| Mylan Specialty L.P. | $17.06 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.72 | 2024 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.84 | 2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $15.03 | 2023 | |
| Horizon Therapeutics Plc | $15.01 | 2022 | |
| Csl Behring | $14.88 | 2023 | Kcentra |
| Evoke Pharma, INC. | $13.98 | 2021 | |
| Lilly USA, LLC | $13.75 | 2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.